Abstract
Worried about rare but severe side effects, 2 years ago Wyeth pulled from the market a new vaccine that prevents rotavirus infection, a major cause of diarrhea. Now two new studies suggest that the risk-benefit calculations in 1999 may have been in error, intensifying questions about the decision to withdraw "RotaShield," as the vaccine is called. The stakes are high for developing countries, where most rotavirus deaths occur.